Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BMJ publication on platelet-rich plasma injections for musculoskeletal soft tissue injuries advises against routine use in clinical practice and highlights the need for high quality research.

In a new paper published this week in the British Medical Journal, Dr David Keene and Professor Keith Willett highlight that routine use of platelet-rich plasma (PRP) in clinical practice for musculoskeletal soft tissue injuries cannot be recommended given the lack of high quality clinical evidence supporting its efficacy.

PRP are prepared from a patient's own blood and have become increasingly popular in sports medicine and orthopaedic practice as treatment for muscle, tendon, and ligament injuries. However, there is insufficient evidence to support the use of PRP and more research is needed to establish its efficacy and how it compares to other active interventions.

The paper is connected with the PATH-2 study, led by researchers at NDORMS, and forms part of a BMJ series of occasional articles that highlight areas of practice where management lacks convincing supporting evidence.

The key messages of the article include:

  • Routine use of autologous platelet-rich plasma (PRP) is not recommended as there is insufficient evidence of clinical efficacy; instead, its use should be restricted to research settings
  • Ensure patients receiving PRP are aware of the limited evidence of efficacy, so that they can make an informed decision about their care
  • Clinicians should be aware of the concentration of PRP, and yield of bioactive proteins, produced by their selected preparation device

PATH-2 study is a randomised controlled trial which is comparing the effects on muscle-tendon function of a standardised PRP preparation versus dry needle injection (control) for non-operatively managed acute Achilles tendon rupture. You can read more about the trial here.

Similar stories

Building a humanoid bioreactor

A humanoid robot is being used at NDORMS in an attempt to grow tendon tissue for repairing shoulder injuries.

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

REF 2021 results for medical research in Oxford

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

New research suggests targeting blood vessels could be key to controlling fibrotic disease

By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.

AI helps to detect bone fractures to 92% accuracy

Research from the Botnar Institute for Musculoskeletal Sciences shows that Artificial intelligence (AI) is an effective tool for fracture detection that has potential to aid clinicians in busy emergency departments.